Award details

Further development of the OURT88/3 strain as a live attenuated vaccine for African swine fever virus

Reference	BBS/E/I/00001801
Principal Investigator / Supervisor	Dr Linda Dixon
Co-Investigators / Co-Supervisors	Dr Christopher Netherton, Dr Geraldine Taylor
Institution	The Pirbright Institute
Department	The Pirbright Institute Department
Funding type	Research
Value (£)	224,512
Status	Current
Type	Institute Project
Start date	01/01/2013
End date	31/12/2016
Duration	47 months

Abstract

African swine fever virus (ASFV) causes a severe disease of domestic pigs that can result in up to 100% mortality and has severe socio-economic impacts. ASFV is endemic in most sub-Saharan African countries and Sardinia. Since introduction of ASF in 2007 to Georgia, the disease has rapidly spread through the Russian Federation and the risk of further spread has increased. The lack of a vaccine limits options for disease control. Attenuated ASFV strain OURT88/3 induces good levels of protection in pigs against lethal challenge with virulent virus. Commercial development of this strain as a vaccine has been hampered by the lack of a suitable cell line to propagate the virus. We have now identified a pig macrophage cell line can be infected by OURT88/3 strain and the virus grown in these cells can still induce protection in pigs. We will investigate the use of this cell line for ASFV vaccine strain production and diagnosis. We will also identify partners for commercial development

Summary

unavailable

Committee	Not funded via Committee
Research Topics	Animal Health, Immunology, Microbiology
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search